Reports of relationship changes after GLP-1–associated weight loss have prompted the label “Ozempic divorces.” The article draws on anecdotes and bariatric-surgery research, neither of which establishes that these medications increase divorce risk.

Growing interest in testosterone for menopause extends beyond its best-supported use for distressing low sexual desire in postmenopausal women. An expert explainer reviews that evidence while highlighting uncertain broader benefits, dosing challenges, and limited long-term safety data.

A South African randomized trial found no significant improvement in the primary composite of preterm birth or low birthweight with antenatal STI screening. Repeat screening yielded a lower preterm-birth rate, a secondary outcome requiring cautious interpretation.

Among middle-aged women taking semaglutide, menopause hormone therapy use was associated with greater weight loss in an observational conference study. Tirzepatide findings were less consistent, and the results have not undergone journal peer review.

According to the report, Mississippi’s highest court required expert testimony to establish that stopping an episiotomy after consent withdrawal was medically feasible. The decision addresses the plaintiff’s evidentiary burden, not blanket authorization to continue unwanted treatment.

Disrupting autism-associated genes produced overlapping gene-expression changes in a human cell model. Researchers also identified ZFX as a potential contributor to female protection, but the findings do not establish protection or treatment benefit in patients.